Stryker (SYK) is breaking support at $325.73, a price level that triggered rallies throughout 2024 but has now failed four separate times since November 2024, each time yielding a 5 percent decline without recovering 20 percent.
The stock closed September 24 at $268.90 before recovering 17.5 percent over the past month. Over the trailing twelve months, SYK is down 6.9 percent including dividends—a sharp divergence from the S&P 500's 13.7 percent return.
What matters for your portfolio: management's October 29 guidance cut. The company trimmed 2026 organic sales growth to 6.5-7 percent (midpoint 6.8 percent), down from prior expectations. The culprit is clear—hip and knee procedures are decelerating, with the market now forecast to grow only 2.5 percent in 2026. Stryker also cited persistent supply constraints in peripheral vascular and execution risk on capital equipment sales.
The MedSurg and Neurotechnology segment posted 9.1 percent organic growth in Q3 with a strong order book, masking weakness elsewhere. Total twelve-month revenue growth through September 30, 2026 was 7.9 percent, well below the 9.8 percent average of the prior two years.
Operating margin sits at 21.8 percent on a trailing twelve-month basis (excluding a $293 million goodwill impairment)—the strongest since late 2016. That profitability cushion is a rebound catalyst if execution improves. But until hip-knee trends stabilize and supply constraints ease, SYK faces structural headwinds. Watch Q4 hip-knee procedure data closely—any further deceleration puts downside risk to current support.
